Additionally, mechanistic studies, such as in vitro knockdown or the overexpression of SARAF in T cells, are planned to elucidate how SARAF elevation contributes to STIM1 and Orai1 downregulation, potentially clarifying its role in MS pathophysiology. This evidence concerns the gene SARAF and myeloid sarcoma.